1,102 results

#108422-AAV5

Ready-to-use AAV5 particles produced from pAAV-CAG-FLEX-Archon1-KGC-EGFP-ER2 (#108422). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-Archon1-KGC-EGFP-ER2 plasmid DNA. CAG-driven, Cre dependent Archon1, an opsin-based fluorescent voltage indicator, fused to EGFP. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Piatkevich et al Nat Chem Biol. 2018 Feb 26. pii: 10.1038

Sept. 17, 2018

Academic Institutions and Nonprofits only

#83899-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-mDlx-GCaMP6f-Fishell-2 (#83899). In addition to the viral particles, you will also receive purified pAAV-mDlx-GCaMP6f-Fishell-2 plasmid DNA. mDlx-driven expression of GCaMP6f. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

June 1, 2020

Academic Institutions and Nonprofits only

#104052-AAVPHP.V1

Ready-to-use AAV PHP.V1 particles produced from pAAV-CAG-DIO-EYFP (#104052). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-EYFP plasmid DNA. CAG-driven, Cre-dependent expression of EYFP. These AAV were produced with the PHP.V1 serotype, which permits efficient transduction of brain vascular cells. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

July 24, 2020

Academic Institutions and Nonprofits only

#176748-AAV9

Ready-to-use AAV9 particles produced from AAV-Syn-H2B-jGCaMP8m-WPRE (#176748). In addition to the viral particles, you will also receive purified AAV-Syn-H2B-jGCaMP8m-WPRE plasmid DNA. Syn-driven expression of histone H2B fused to calcium sensor GCaMP8m. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Feb. 24, 2023

Academic Institutions and Nonprofits only

#135633-AAV1

Ready-to-use AAV1 particles produced from pAAV-S5E2-C1V1-eYFP (#135633). In addition to the viral particles, you will also receive purified pAAV-S5E2-C1V1-eYFP plasmid DNA. Expression of red-shifted opsin C1V1 fused to EYFP under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only

#176756-AAV1

Ready-to-use AAV1 particles produced from AAV-EF1a-jGCaMP8f-WPRE (#176756). In addition to the viral particles, you will also receive purified AAV-EF1a-jGCaMP8f-WPRE plasmid DNA. EF1a-driven expression of calcium sensor GCaMP8f. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Feb. 24, 2023

Academic Institutions and Nonprofits only

#153286-AAV2

Ready-to-use AAV2 particles produced from pAAV-hsyn-GRAB_Ado1.0med (#153286). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_Ado1.0med plasmid DNA. Synapsin-driven expression of GRAB_Ado1.0med adenosine sensor in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Wu et al Proc Natl Acad Sci U S A. 2023 Apr 4;120

Nov. 13, 2025

Academic Institutions and Nonprofits only

#105542-AAV1

Ready-to-use AAV1 particles produced from pENN.AAV.CB7.CI.eGFP.WPRE.rBG (#105542). In addition to the viral particles, you will also receive purified pENN.AAV.CB7.CI.eGFP.WPRE.rBG plasmid DNA. CB7-driven eGFP. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

May 8, 2018

Academic Institutions and Nonprofits only

#135635-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-S5E2-Gq-P2A-dTomato (#135635). In addition to the viral particles, you will also receive purified pAAV-S5E2-Gq-P2A-dTomato plasmid DNA. Expression of Gq-DREADD and dTomato (physically separate) under the control of the E2 regulatory element. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only

#157970-AAV.A12.T

Ready-to-use AAV44.9(E531D) in PBS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#35512-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-hChR2(E123T/T159C)-mCherry (#35512). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(E123T/T159C)-mCherry plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin E123T/T159C mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Mattis et al Nat Methods. 2011 Dec 18;9(2):159-72. do

Nov. 13, 2025

Academic Institutions and Nonprofits only

#98930-AAV1

Ready-to-use AAV1 particles produced from pENN.AAV.GFAP.iGluSnFr.WPRE.SV40 (#98930). In addition to the viral particles, you will also receive purified pENN.AAV.GFAP.iGluSnFr.WPRE.SV40 plasmid DNA. GFAP-driven glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2013 Feb;10(2):162-70. doi:

March 15, 2018

Academic Institutions and Nonprofits only

#179255-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV-CAG-jGCaMP8m-WPRE (#179255). In addition to the viral particles, you will also receive purified AAV-CAG-jGCaMP8m-WPRE plasmid DNA. CAG-driven expression of calcium sensor GCaMP8m. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Loren Looger

March 18, 2024

Academic Institutions and Nonprofits only

#172923-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSynapsin1-axon-jGCaMP8f-P2A-mRuby3 (#172923). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-jGCaMP8f-P2A-mRuby3 plasmid DNA. hSyn-driven expression of jGCaMP8f in axons with cytosolic expression of mRuby3. These AAV preparations are suitable purity for injection into animals.

GENIE Project

June 8, 2023

Academic Institutions and Nonprofits only

#18916-AAV1

Ready-to-use AAV1 particles produced from AAV-FLEX-rev-ChR2(H134R)-mCherry (#18916). In addition to the viral particles, you will also receive purified AAV-FLEX-rev-ChR2(H134R)-mCherry plasmid DNA. CAG-driven, cre-dependent, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Scott Sternson

Atasoy et al J Neurosci. 2008 Jul 9. 28(28):7025-30.

Feb. 21, 2018

Academic Institutions and Nonprofits only

#140135-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-EF1a-iCreV (#140135). In addition to the viral particles, you will also receive purified pAAV-EF1a-iCreV plasmid DNA. EF1a-driven, light-inducible iCreV recombinase for spatiotemporally precise optogenomic modifications. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Yao et al Nat Methods. 2020 Mar 23. pii: 10.1038/s

Sept. 15, 2021

Academic Institutions and Nonprofits only

#100832-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSyn.CaMPARI.WPRE.SV40 (#100832). In addition to the viral particles, you will also receive purified pAAV.hSyn.CaMPARI.WPRE.SV40 plasmid DNA. Synapsin-driven, photoconvertible (irreversible green-to-red) calcium integrator. These AAV preparations are suitable purity for injection into animals.

Loren Looger, Eric Schreiter

Fosque et al Science. 2015 Feb 13;347(6223):755-60. d

April 6, 2018

Academic Institutions and Nonprofits only

#167572-AAV1

Ready-to-use AAV1 particles produced from AAV-hSyn-Ribo-jGCaMP8s (#167572). In addition to the viral particles, you will also receive purified AAV-hSyn-Ribo-jGCaMP8s plasmid DNA. Synapsin-driven neuronal expression of soma-targeted (RL-10, ribosomal tag) jGCaMP8s. These AAV preparations are suitable purity for injection into animals.

Marianne Fyhn

Grodem et al Nat Commun. 2023 Feb 4;14(1):608. doi: 1

Dec. 18, 2024

Academic Institutions and Nonprofits only

#114470-AAV2

Ready-to-use AAV2 particles produced from pAAV-Ef1a-mCherry (#114470). In addition to the viral particles, you will also receive purified pAAV-Ef1a-mCherry plasmid DNA. EF1a-driven mCherry expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Nov. 29, 2021

Academic Institutions and Nonprofits only

#230884-AAV2

Ready-to-use AAV2 particles produced from AiP15646: pAAV-AiE1426m_3xC2-minBG-SYFP2-WPRE3-BGHpA (Alias: CN5646) (#230884). In addition to the viral particles, you will also receive purified AiP15646: pAAV-AiE1426m_3xC2-minBG-SYFP2-WPRE3-BGHpA (Alias: CN5646) plasmid DNA. minBG-driven expression of SYFP2 in cortical and striatal Sst-Chodl neurons. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Nov. 14, 2025

Academic Institutions and Nonprofits only